Drugs / ChAdOx2 HAV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03027193 | Mar 2017 → Jan 2020 | Crohn disease, Mycobacterium avium complex disease | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx2 HAV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03027193 ↗ |
| Modality | Vaccine | “The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2” NCT03027193 ↗ |
| Route | Intramuscular | “through intramuscular route” NCT03027193 ↗ |